Leap Therapeutics Inc (STU:5MC)
€ 2.62 -0.1 (-3.68%) Market Cap: 101.82 Mil Enterprise Value: 42.34 Mil PE Ratio: 0 PB Ratio: 2.27 GF Score: 35/100

Leap Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript

Sep 11, 2023 / 11:00AM GMT
Release Date Price: €1.7 (-7.10%)
Operator

My name is Emily Bodnar and I'm an equity research analyst at H.C. Wainwright. I'm pleased to introduce our next presenter, Doug Onsi, who is the Chief Executive Officer of Leap Therapeutics.

Doug Onsi
Leap Therapeutics, Inc. - President & CEO

Thank you. It's a pleasure to be here virtually at the H.C. Wainwright 25th Annual Investment Conference. I'm Doug Onsi, the President and CEO of Leap Therapeutics. And I'm proud to be able to give you an update on the clinical development of DKN-01 and the milestones ahead in the coming months. My presentation will include forward-looking statements. So I encourage you to review our securities acts filings.

Leap Therapeutics is a biomarker-driven oncology drug development company with a strategic focus on gastrointestinal cancers. We're developing a pipeline of targeted and immuno-oncology antibody therapeutics led by DKN-01, our Anti-DKK1 monoclonal antibody that has generated single-agent activity in three different tumor types. Compelling combination activity with anti-PD-1 and PD-L1 antibodies and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot